Oxford Global Conferences are proud to present the 4th Annual Biosimilars & Biobetters Congress taking place on April 18 – 19 2016 at the Hotel Novotel London West in London, UK. Together with the 9th Annual Proteins and Antibodies Congress 2016 and the 3rd Annual Oxford Global Peptides Congress 2016, the 3 events provide a unique opportunity for over 350 global leaders in the biologics industry to exchange knowledge and experience, share their ideas on innovative practices, and benefit from engaging networking opportunities with peers in the biosimilars and biologics field.
The rate at which biosimilars are being developed and approved is gaining momentum, and the industry is likely to reach a projected value of up to $20 billion by 2020. As ever more biosimilars reach the clinical and commercial stages, we will bring together key scientific and business minds to address the major challenges and most exciting opportunities that lie ahead for the industry.
Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable knowledge share and facilitate idea exchange.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Francesca Lord at email@example.com.
2015 Confirmed Speakers Included
- Ali Atta – Takeda
- Hubert Chen – Pfenex
- Anna Cyranka – Polpharma Biologics
- Rakesh Dixit – Global Head Biologics Safety Assessment, Patholoy & LAR, MedImmune
- Atanas Dmitrox – Merck
- Katalin Egyed – Egis Pharmaceuticals
- Mourad Farouk – Medical Affairs Biosimilars, Biogen Idec
- Uwe Gudat – Medical Safety, Biosimilars, Merck Serono
- Zsolt Holló – Biologics Advisory, Egis Pharmaceuticals
- Roman Ivanov – Research & Development, Biocad
- Alex Kudrin – Global Development, Celltrion
- Michael Leach – Biosimilars and Centres for Therapeutic Innovation, Pfizer
- Emmanuelle Lepine – Alvotech
- Bernd Liedert – Boehringer Ingelheim
- Steinar Madsen – Norwegian Medicines Agency
- Leandro Mieravilla – Cassara Biotech
- Julie O’Brien – Emerging Markets Regulatory Policy, Worldwide Safety Regulatory, Pfizer
- Devrim Satik – Sanofi
- Ozdemir Sengoeren – UCB
- Meenu Wadhwa – Ctyokines & Growth Factors, NIBSC
- Keith Watson – Abbvie
- Atakan Yesil – Abbott
In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with our advisory board members including VPs, Directors, Senior Research Fellows and Professors from global pharmaceutical organisations and leading research institutions.
Day 1 – Market Access Strategies, Opportunities and Commercial Challenges
Day One will explore business and commercial aspects of the biosimilar landscape, with topics including key market access and regulatory issues. Our esteemed panel of expert speakers will cover updates on biosimilar and biobetter competition, legal affairs, and market strategies, and how these areas are affecting those working in the industry right now. Global access difficulties and the future possibilities for the biosimilars products will be discussed by those who are the forefront of the field.
- Updates on biosimilar and biobetter regulatory guidelines
- Streamlining approval and access for follow-on biologics
- Opportunities and challenges in bringing future biosimilars to market
- Emerging markets and the establishment of biosimilar products
- Technology transfer strategies for market access
- Successful biosimilar product case studies from benchtop to market
Day 2 – Biosimilar and Biobetter Development
Day Two will look at the development of both biosimilar and biobetter products at preclinical and clinical stages. Representatives from leading international biosimilar industry organisations will provide exciting case studies detailing the planning and execution of effective biosimilar clinical trials, as well as looking at the optimisation of analytical testing in the preclinical phase to better advance the approval of products.
- Biosimilar and biobetter development and clinical case studies
- Designing and conducting global clinical trials
- Designing clinical models and using data to effectively demonstrate biosimilarity
- Opportunities in biobetters development
- The latest on demonstrating interchangeability
- Approaches to harmonizing immunogenicity testing
- Novel techniques and technologies for characterisation, assay development and extrapolation
Submit a poster
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
How to submit your abstract
We will require:
- Poster title, Abstract (200 words or less)
- Principal author, Organisation, Mailing address
- Email, Telephone, Fax
- Additional authors
In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size. To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, so please book soon!